Monday, August 17, 2020

Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations

In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

from Latest Science News -- ScienceDaily https://ift.tt/317NlC5
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

One tiny mutation may explain how bat viruses become human threats

Scientists found that one tiny genetic change can completely alter how a coronavirus behaves in different species. Comparing SARS-CoV-2 with...